` ARAY (Accuray Inc) vs S&P 500 Comparison - Alpha Spread

ARAY
vs
S&P 500

Over the past 12 months, ARAY has underperformed S&P 500, delivering a return of -51% compared to the S&P 500's +14% growth.

Stocks Performance
ARAY vs S&P 500

Loading
ARAY
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
ARAY vs S&P 500

Loading
ARAY
S&P 500
Difference
www.alphaspread.com

Performance By Year
ARAY vs S&P 500

Loading
ARAY
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Accuray Inc vs Peers

No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Accuray Inc
Glance View

Market Cap
102.8m USD
Industry
Health Care

Accuray, Inc. is a radiation oncology company. The company is headquartered in Sunnyvale, California and currently employs 995 full-time employees. The company went IPO on 2007-02-08. The firm develops, manufactures, sells and supports market-changing solutions that are designed to deliver radiation treatments. The firm's technologies include the CyberKnife and TomoTherapy platforms, including the Radixact System. The CyberKnife and TomoTherapy platform, which are designed to deliver treatments, including stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image-guided radiation therapy (IGRT) and adaptive radiation therapy (ART). The CyberKnife Systems are robotic systems that are used to treat various types of cancer and tumors throughout the body. The CyberKnife Systems track, detect and correct for tumor and patient movement in real-time during the procedure. The TomoTherapy Systems include the TomoTherapy H Series with configuration options of TomoH, TomoHD and TomoHDA.

ARAY Intrinsic Value
5.1033 USD
Undervaluation 82%
Intrinsic Value
Price
Back to Top